Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASN51 + paroxetine
- Development stage
- Unknown
- Lead developer
- Asceneuron
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ASN51 + paroxetine is a **combination of ASN51, an oral small molecule inhibitor of O-GlcNAcase (OGA) under development for neurodegenerative diseases (notably Alzheimer's disease), and paroxetine, a selective serotonin reuptake inhibitor (SSRI) approved for depression, anxiety disorders, and other psychiatric indications. ASN51 inhibits OGA to reduce tau protein aggregation in the central nervous system, which is believed to slow disease progression in neurodegenerative disorders. Paroxetine selectively blocks the serotonin reuptake transporter, leading to increased synaptic serotonin, and is used in the treatment of depression, anxiety disorders, and related conditions.** Clinical studies have investigated the drug-drug interaction profile between ASN51 and paroxetine in healthy subjects[1][3][4][7].
- Other names
- ASN51 + paroxetineparoxetine hydrochloride
02
Targets
SERT (Sodium-dependent serotonin transporter)OGA (Protein O-GlcNAcase)
Beyond the preview
Go deeper on ASN51 + paroxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASN51 + paroxetine.